Stock Analysis
Top SEHK Growth Companies With High Insider Ownership In October 2024
Reviewed by Simply Wall St
As global markets experience varied economic shifts, with U.S. stocks reaching new highs and Chinese equities facing declines, the Hong Kong market remains a focal point for investors seeking growth opportunities amidst these fluctuations. In this context, identifying companies with high insider ownership can be particularly insightful, as such alignment often signals confidence in a company's potential to navigate current economic conditions effectively.
Top 10 Growth Companies With High Insider Ownership In Hong Kong
| Name | Insider Ownership | Earnings Growth |
| Laopu Gold (SEHK:6181) | 36.4% | 33.2% |
| Akeso (SEHK:9926) | 20.5% | 53% |
| Fenbi (SEHK:2469) | 33.1% | 22.4% |
| Xiamen Yan Palace Bird's Nest Industry (SEHK:1497) | 26.7% | 23.8% |
| Zylox-Tonbridge Medical Technology (SEHK:2190) | 18.8% | 69.8% |
| Pacific Textiles Holdings (SEHK:1382) | 11.2% | 37.7% |
| DPC Dash (SEHK:1405) | 38.1% | 104.2% |
| Biocytogen Pharmaceuticals (Beijing) (SEHK:2315) | 13.9% | 109.2% |
| Beijing Airdoc Technology (SEHK:2251) | 29.1% | 93.4% |
| Zhejiang Leapmotor Technology (SEHK:9863) | 15% | 69.7% |
We'll examine a selection from our screener results.
ESR Group (SEHK:1821)
Simply Wall St Growth Rating: ★★★★☆☆
Overview: ESR Group Limited operates in logistics real estate development, leasing, and management across various regions including Hong Kong, China, Japan, South Korea, Australia, New Zealand, Southeast Asia, India, Europe and internationally with a market cap of HK$52.05 billion.
Operations: The company's revenue segments include Fund Management at $628 million, New Economy Development at $113.33 million, and Investment at -$106.44 million.
Insider Ownership: 13%
Revenue Growth Forecast: 16.4% p.a.
ESR Group is poised for growth, with revenue expected to increase by 16.4% annually, outpacing the Hong Kong market average. Despite recent financial setbacks, including a US$218.72 million net loss for H1 2024 due to non-cash asset revaluations, the company is forecasted to return to profitability within three years. The transition of leadership from Jeffrey Perlman to Brett Krause may influence strategic direction but hasn't led to significant insider trading activity recently.
- Click here and access our complete growth analysis report to understand the dynamics of ESR Group.
- The valuation report we've compiled suggests that ESR Group's current price could be inflated.
Biocytogen Pharmaceuticals (Beijing) (SEHK:2315)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Biocytogen Pharmaceuticals (Beijing) Co., Ltd. is a biotechnology company focused on the research and development of antibody-based drugs across China, the United States, and internationally, with a market cap of HK$2.98 billion.
Operations: Biocytogen Pharmaceuticals generates revenue from several segments, including CN¥75.50 million from Gene Editing, CN¥205.83 million from Antibody Development, CN¥354.44 million from Animal Models Selling, and CN¥185.41 million from Pre-Clinical Pharmacology and Efficacy Evaluation.
Insider Ownership: 13.9%
Revenue Growth Forecast: 21.5% p.a.
Biocytogen Pharmaceuticals (Beijing) demonstrates strong growth potential, with revenue forecasted to rise 21.5% annually, surpassing the Hong Kong market average. Recent earnings show a significant reduction in net loss to CNY 50.67 million for H1 2024, attributed to high-margin antibody licensing and expanding overseas sales. Despite share price volatility and low projected return on equity of 15.4%, strategic partnerships like those with IDEAYA Biosciences enhance its innovative pipeline and future profitability prospects.
- Delve into the full analysis future growth report here for a deeper understanding of Biocytogen Pharmaceuticals (Beijing).
- Upon reviewing our latest valuation report, Biocytogen Pharmaceuticals (Beijing)'s share price might be too pessimistic.
Lianlian DigiTech (SEHK:2598)
Simply Wall St Growth Rating: ★★★★★☆
Overview: Lianlian DigiTech Co., Ltd., along with its subsidiaries, offers digital payment and value-added services to small and midsized merchants and enterprises in China, with a market cap of approximately HK$10.56 billion.
Operations: The company's revenue is derived from three main segments: Global Payment (CN¥722.95 million), Domestic Payment (CN¥309.92 million), and Value-Added Services (CN¥153.01 million).
Insider Ownership: 19.7%
Revenue Growth Forecast: 22.3% p.a.
Lianlian DigiTech is positioned for strong growth, with revenue expected to increase by 22.3% annually, significantly outpacing the Hong Kong market average. The company reported H1 2024 sales of CNY 617.39 million, up from CNY 440.59 million a year earlier, while reducing its net loss to CNY 351.29 million. Despite a low projected return on equity of 14.3%, Lianlian DigiTech's path to profitability within three years underscores its growth trajectory amidst high insider ownership dynamics.
- Dive into the specifics of Lianlian DigiTech here with our thorough growth forecast report.
- In light of our recent valuation report, it seems possible that Lianlian DigiTech is trading beyond its estimated value.
Turning Ideas Into Actions
- Investigate our full lineup of 47 Fast Growing SEHK Companies With High Insider Ownership right here.
- Shareholder in one or more of these companies? Ensure you're never caught off-guard by adding your portfolio in Simply Wall St for timely alerts on significant stock developments.
- Join a community of smart investors by using Simply Wall St. It's free and delivers expert-level analysis on worldwide markets.
Interested In Other Possibilities?
- Explore high-performing small cap companies that haven't yet garnered significant analyst attention.
- Diversify your portfolio with solid dividend payers offering reliable income streams to weather potential market turbulence.
- Find companies with promising cash flow potential yet trading below their fair value.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.The analysis only considers stock directly held by insiders. It does not include indirectly owned stock through other vehicles such as corporate and/or trust entities. All forecast revenue and earnings growth rates quoted are in terms of annualised (per annum) growth rates over 1-3 years.
Valuation is complex, but we're here to simplify it.
Discover if Biocytogen Pharmaceuticals (Beijing) might be undervalued or overvalued with our detailed analysis, featuring fair value estimates, potential risks, dividends, insider trades, and its financial condition.
Access Free AnalysisHave feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com
About SEHK:2315
Biocytogen Pharmaceuticals (Beijing)
A biotechnology company, engages in the research and development of antibody-based drugs in the People’s Republic of China, the United States, and internationally.
